Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
Identifieur interne : 000C75 ( PubMed/Checkpoint ); précédent : 000C74; suivant : 000C76Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
Auteurs : Giuseppe Saglio [Italie] ; Philipp Le Coutre [Allemagne] ; Jorge Cortes [États-Unis] ; Ji Mayer [République tchèque] ; Philip Rowlings [Australie] ; François-Xavier Mahon [France] ; Glenn Kroog [États-Unis] ; Kyna Gooden [États-Unis] ; Milayna Subar [États-Unis] ; Neil P. Shah [États-Unis]Source :
- Annals of hematology [ 1432-0584 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Dasatinib (effets indésirables), Essais cliniques comme sujet (), Femelle, Humains, Incidence, Inhibiteurs de protéines kinases (effets indésirables), Ischémie (), Ischémie (épidémiologie), Leucémie myéloïde chronique BCR-ABL positive (traitement médicamenteux), Maladies cardiovasculaires (), Maladies cardiovasculaires (épidémiologie), Mâle, Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Sujet âgé, Tumeurs de la prostate (traitement médicamenteux), Évaluation de résultat (soins) ().
- MESH :
- effets indésirables : Dasatinib, Inhibiteurs de protéines kinases, Protocoles de polychimiothérapie antinéoplasique.
- traitement médicamenteux : Leucémie myéloïde chronique BCR-ABL positive, Tumeurs de la prostate.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- épidémiologie : Ischémie, Maladies cardiovasculaires.
- Adulte, Adulte d'âge moyen, Essais cliniques comme sujet, Femelle, Humains, Incidence, Ischémie, Maladies cardiovasculaires, Mâle, Sujet âgé, Évaluation de résultat (soins).
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Cardiovascular Diseases (chemically induced), Cardiovascular Diseases (epidemiology), Clinical Trials as Topic (methods), Clinical Trials as Topic (statistics & numerical data), Dasatinib (adverse effects), Female, Humans, Incidence, Ischemia (chemically induced), Ischemia (epidemiology), Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy), Male, Middle Aged, Outcome Assessment (Health Care) (methods), Outcome Assessment (Health Care) (statistics & numerical data), Prostatic Neoplasms (drug therapy), Protein Kinase Inhibitors (adverse effects).
- MESH :
- chemical , adverse effects : Dasatinib, Protein Kinase Inhibitors.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- chemically induced : Cardiovascular Diseases, Ischemia.
- drug therapy : Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Prostatic Neoplasms.
- epidemiology : Cardiovascular Diseases, Ischemia.
- methods : Clinical Trials as Topic, Outcome Assessment (Health Care).
- statistics & numerical data : Clinical Trials as Topic, Outcome Assessment (Health Care).
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Female, Humans, Incidence, Male, Middle Aged.
Abstract
With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY). Overall, 2-4% of dasatinib-treated patients had cardiovascular ischemic events. Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18). Most cardiovascular ischemic events occurred within 1 year of initiating dasatinib (pooled 69/96; DASISION 7/10; READY 16/18). Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations.
DOI: 10.1007/s00277-017-3012-z
PubMed: 28534184
Affiliations:
- Allemagne, Australie, France, Italie, République tchèque, États-Unis
- Aquitaine, Berlin, Californie, Moravie, New Jersey, Nouvelle-Aquitaine, Texas
- Berlin, Bordeaux, Brno
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28534184Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.</title><author><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name><affiliation wicri:level="1"><nlm:affiliation>Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, 10043, Orbassano-Torino, Italy. giuseppe.saglio@unito.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, 10043, Orbassano-Torino</wicri:regionArea><wicri:noRegion>Orbassano-Torino</wicri:noRegion></affiliation></author><author><name sortKey="Le Coutre, Philipp" sort="Le Coutre, Philipp" uniqKey="Le Coutre P" first="Philipp" last="Le Coutre">Philipp Le Coutre</name><affiliation wicri:level="3"><nlm:affiliation>Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Cortes, Jorge" sort="Cortes, Jorge" uniqKey="Cortes J" first="Jorge" last="Cortes">Jorge Cortes</name><affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Mayer, Ji" sort="Mayer, Ji" uniqKey="Mayer J" first="Ji" last="Mayer">Ji Mayer</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Brno</wicri:regionArea><placeName><settlement type="city">Brno</settlement><region>Moravie</region></placeName></affiliation></author><author><name sortKey="Rowlings, Philip" sort="Rowlings, Philip" uniqKey="Rowlings P" first="Philip" last="Rowlings">Philip Rowlings</name><affiliation wicri:level="1"><nlm:affiliation>Calvary Mater Newcastle Hospital, University of Newcastle, Waratah, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Calvary Mater Newcastle Hospital, University of Newcastle, Waratah, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Mahon, Francois Xavier" sort="Mahon, Francois Xavier" uniqKey="Mahon F" first="François-Xavier" last="Mahon">François-Xavier Mahon</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Hématologie et Service des Maladies du Sang, Bordeaux et Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie et Service des Maladies du Sang, Bordeaux et Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Kroog, Glenn" sort="Kroog, Glenn" uniqKey="Kroog G" first="Glenn" last="Kroog">Glenn Kroog</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Gooden, Kyna" sort="Gooden, Kyna" uniqKey="Gooden K" first="Kyna" last="Gooden">Kyna Gooden</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Subar, Milayna" sort="Subar, Milayna" uniqKey="Subar M" first="Milayna" last="Subar">Milayna Subar</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Shah, Neil P" sort="Shah, Neil P" uniqKey="Shah N" first="Neil P" last="Shah">Neil P. Shah</name><affiliation wicri:level="2"><nlm:affiliation>UCSF School of Medicine, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCSF School of Medicine, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28534184</idno><idno type="pmid">28534184</idno><idno type="doi">10.1007/s00277-017-3012-z</idno><idno type="wicri:Area/PubMed/Corpus">000835</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000835</idno><idno type="wicri:Area/PubMed/Curation">000832</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000832</idno><idno type="wicri:Area/PubMed/Checkpoint">000832</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000832</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.</title><author><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name><affiliation wicri:level="1"><nlm:affiliation>Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, 10043, Orbassano-Torino, Italy. giuseppe.saglio@unito.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, 10043, Orbassano-Torino</wicri:regionArea><wicri:noRegion>Orbassano-Torino</wicri:noRegion></affiliation></author><author><name sortKey="Le Coutre, Philipp" sort="Le Coutre, Philipp" uniqKey="Le Coutre P" first="Philipp" last="Le Coutre">Philipp Le Coutre</name><affiliation wicri:level="3"><nlm:affiliation>Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Cortes, Jorge" sort="Cortes, Jorge" uniqKey="Cortes J" first="Jorge" last="Cortes">Jorge Cortes</name><affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Mayer, Ji" sort="Mayer, Ji" uniqKey="Mayer J" first="Ji" last="Mayer">Ji Mayer</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Brno</wicri:regionArea><placeName><settlement type="city">Brno</settlement><region>Moravie</region></placeName></affiliation></author><author><name sortKey="Rowlings, Philip" sort="Rowlings, Philip" uniqKey="Rowlings P" first="Philip" last="Rowlings">Philip Rowlings</name><affiliation wicri:level="1"><nlm:affiliation>Calvary Mater Newcastle Hospital, University of Newcastle, Waratah, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Calvary Mater Newcastle Hospital, University of Newcastle, Waratah, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Mahon, Francois Xavier" sort="Mahon, Francois Xavier" uniqKey="Mahon F" first="François-Xavier" last="Mahon">François-Xavier Mahon</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Hématologie et Service des Maladies du Sang, Bordeaux et Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie et Service des Maladies du Sang, Bordeaux et Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Kroog, Glenn" sort="Kroog, Glenn" uniqKey="Kroog G" first="Glenn" last="Kroog">Glenn Kroog</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Gooden, Kyna" sort="Gooden, Kyna" uniqKey="Gooden K" first="Kyna" last="Gooden">Kyna Gooden</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Subar, Milayna" sort="Subar, Milayna" uniqKey="Subar M" first="Milayna" last="Subar">Milayna Subar</name><affiliation wicri:level="2"><nlm:affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bristol-Myers Squibb, Princeton, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Shah, Neil P" sort="Shah, Neil P" uniqKey="Shah N" first="Neil P" last="Shah">Neil P. Shah</name><affiliation wicri:level="2"><nlm:affiliation>UCSF School of Medicine, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCSF School of Medicine, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Annals of hematology</title><idno type="eISSN">1432-0584</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Cardiovascular Diseases (chemically induced)</term><term>Cardiovascular Diseases (epidemiology)</term><term>Clinical Trials as Topic (methods)</term><term>Clinical Trials as Topic (statistics & numerical data)</term><term>Dasatinib (adverse effects)</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Ischemia (chemically induced)</term><term>Ischemia (epidemiology)</term><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)</term><term>Male</term><term>Middle Aged</term><term>Outcome Assessment (Health Care) (methods)</term><term>Outcome Assessment (Health Care) (statistics & numerical data)</term><term>Prostatic Neoplasms (drug therapy)</term><term>Protein Kinase Inhibitors (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Dasatinib (effets indésirables)</term><term>Essais cliniques comme sujet ()</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Ischémie ()</term><term>Ischémie (épidémiologie)</term><term>Leucémie myéloïde chronique BCR-ABL positive (traitement médicamenteux)</term><term>Maladies cardiovasculaires ()</term><term>Maladies cardiovasculaires (épidémiologie)</term><term>Mâle</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Sujet âgé</term><term>Tumeurs de la prostate (traitement médicamenteux)</term><term>Évaluation de résultat (soins) ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dasatinib</term><term>Protein Kinase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cardiovascular Diseases</term><term>Ischemia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Dasatinib</term><term>Inhibiteurs de protéines kinases</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cardiovascular Diseases</term><term>Ischemia</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term><term>Outcome Assessment (Health Care)</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Clinical Trials as Topic</term><term>Outcome Assessment (Health Care)</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie myéloïde chronique BCR-ABL positive</term><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Ischémie</term><term>Maladies cardiovasculaires</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Ischémie</term><term>Maladies cardiovasculaires</term><term>Mâle</term><term>Sujet âgé</term><term>Évaluation de résultat (soins)</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY). Overall, 2-4% of dasatinib-treated patients had cardiovascular ischemic events. Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18). Most cardiovascular ischemic events occurred within 1 year of initiating dasatinib (pooled 69/96; DASISION 7/10; READY 16/18). Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28534184</PMID><DateCreated><Year>2017</Year><Month>05</Month><Day>23</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0584</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of hematology</Title><ISOAbbreviation>Ann. Hematol.</ISOAbbreviation></Journal><ArticleTitle>Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.</ArticleTitle><Pagination><MedlinePgn>1303-1313</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00277-017-3012-z</ELocationID><Abstract><AbstractText>With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY). Overall, 2-4% of dasatinib-treated patients had cardiovascular ischemic events. Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18). Most cardiovascular ischemic events occurred within 1 year of initiating dasatinib (pooled 69/96; DASISION 7/10; READY 16/18). Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saglio</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, 10043, Orbassano-Torino, Italy. giuseppe.saglio@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>le Coutre</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortes</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Jiří</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowlings</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Calvary Mater Newcastle Hospital, University of Newcastle, Waratah, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahon</LastName><ForeName>François-Xavier</ForeName><Initials>FX</Initials><AffiliationInfo><Affiliation>Laboratoire d'Hématologie et Service des Maladies du Sang, Bordeaux et Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kroog</LastName><ForeName>Glenn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gooden</LastName><ForeName>Kyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subar</LastName><ForeName>Milayna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Neil P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>UCSF School of Medicine, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Ann Hematol</MedlineTA><NlmUniqueID>9107334</NlmUniqueID><ISSNLinking>0939-5555</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>RBZ1571X5H</RegistryNumber><NameOfSubstance UI="D000069439">Dasatinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2016;57(6):1300-10</RefSource><PMID Version="1">26373533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Jun 15;109(12):5143-50</RefSource><PMID Version="1">17317857</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Jun 17;362(24):2251-9</RefSource><PMID Version="1">20525993</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Jul 1;26(19):3204-12</RefSource><PMID Version="1">18541900</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Zhonghua Xue Ye Xue Za Zhi. 2012 Nov;33(11):889-95</RefSource><PMID Version="1">23363742</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BioDrugs. 2014 Feb;28(1):17-26</RefSource><PMID Version="1">24043361</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Hematol. 2015 Apr;90(4):E66-72</RefSource><PMID Version="1">25580915</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Nov 7;369(19):1783-96</RefSource><PMID Version="1">24180494</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Oncol. 2016 Feb 4;:null</RefSource><PMID Version="1">26847662</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51</RefSource><PMID Version="1">23092636</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Apr 15;109(8):3207-13</RefSource><PMID Version="1">17185463</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2016 May;30(5):1044-54</RefSource><PMID Version="1">26837842</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Mar 15;109(6):2303-9</RefSource><PMID Version="1">17138817</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2015 Feb 5;125(6):901-6</RefSource><PMID Version="1">25525119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Jun 18;113(25):6322-9</RefSource><PMID Version="1">19369231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Dec;14(13):1307-16</RefSource><PMID Version="1">24211163</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2015 Jan 27;131(4):e29-322</RefSource><PMID Version="1">25520374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 May 15;109(10):4143-50</RefSource><PMID Version="1">17264298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2016 Jul;30(7):1593-6</RefSource><PMID Version="1">26686247</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Jun 17;362(24):2260-70</RefSource><PMID Version="1">20525995</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2016 Jul 10;34(20):2333-40</RefSource><PMID Version="1">27217448</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2014 Feb;99(2):205-8</RefSource><PMID Version="1">24497557</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069439" MajorTopicYN="N">Dasatinib</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015464" MajorTopicYN="N">Leukemia, Myelogenous, Chronic, BCR-ABL Positive</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment (Health Care)</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular</Keyword><Keyword MajorTopicYN="N">Chronic myeloid leukemia</Keyword><Keyword MajorTopicYN="N">Dasatinib</Keyword><Keyword MajorTopicYN="N">Ischemic</Keyword><Keyword MajorTopicYN="N">Tyrosine kinase inhibitors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28534184</ArticleId><ArticleId IdType="doi">10.1007/s00277-017-3012-z</ArticleId><ArticleId IdType="pii">10.1007/s00277-017-3012-z</ArticleId><ArticleId IdType="pmc">PMC5486782</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Italie</li><li>République tchèque</li><li>États-Unis</li></country><region><li>Aquitaine</li><li>Berlin</li><li>Californie</li><li>Moravie</li><li>New Jersey</li><li>Nouvelle-Aquitaine</li><li>Texas</li></region><settlement><li>Berlin</li><li>Bordeaux</li><li>Brno</li></settlement></list><tree><country name="Italie"><noRegion><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name></noRegion></country><country name="Allemagne"><region name="Berlin"><name sortKey="Le Coutre, Philipp" sort="Le Coutre, Philipp" uniqKey="Le Coutre P" first="Philipp" last="Le Coutre">Philipp Le Coutre</name></region></country><country name="États-Unis"><region name="Texas"><name sortKey="Cortes, Jorge" sort="Cortes, Jorge" uniqKey="Cortes J" first="Jorge" last="Cortes">Jorge Cortes</name></region><name sortKey="Gooden, Kyna" sort="Gooden, Kyna" uniqKey="Gooden K" first="Kyna" last="Gooden">Kyna Gooden</name><name sortKey="Kroog, Glenn" sort="Kroog, Glenn" uniqKey="Kroog G" first="Glenn" last="Kroog">Glenn Kroog</name><name sortKey="Shah, Neil P" sort="Shah, Neil P" uniqKey="Shah N" first="Neil P" last="Shah">Neil P. Shah</name><name sortKey="Subar, Milayna" sort="Subar, Milayna" uniqKey="Subar M" first="Milayna" last="Subar">Milayna Subar</name></country><country name="République tchèque"><region name="Moravie"><name sortKey="Mayer, Ji" sort="Mayer, Ji" uniqKey="Mayer J" first="Ji" last="Mayer">Ji Mayer</name></region></country><country name="Australie"><noRegion><name sortKey="Rowlings, Philip" sort="Rowlings, Philip" uniqKey="Rowlings P" first="Philip" last="Rowlings">Philip Rowlings</name></noRegion></country><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Mahon, Francois Xavier" sort="Mahon, Francois Xavier" uniqKey="Mahon F" first="François-Xavier" last="Mahon">François-Xavier Mahon</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000C75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28534184
|texte= Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28534184" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |